Trending...
- Thermo Fisher Scientific Acquires Viral Vector Manufacturing Business from Novasep
- Boston: Mayor Walsh announces 2021 day of celebration in honor of Rev. Dr. Martin Luther King Jr.
- Boston: January 2021: Latest updates from the Department of Neighborhood Development
WALTHAM, Mass. - BostonChron -- Nova Biomedical announces the availability of Nova Primary, a rapid, accurate, easy to use blood glucose reference analyzer. Nova Primary fills the need for a new glucose reference correlation analyzer to replace the YSI 2300 (YSI, Inc., Yellow Springs, OH).
Manufacturers of blood glucose measuring devices and clinical researchers have relied on the YSI 2300 as a reference and correlation analyzer. However, as of July 2021, YSI will no longer support the analyzer, and its discontinuation has left a void. The Nova Primary analyzer fills that need. It will be available in December, 2020 for CE regulated countries and was submitted to the U.S. FDA in November 2020.
Like the YSI 2300, Nova Primary uses a single, reusable glucose electrochemical sensor based on glucose oxidase and has a measurement range of 0-1000 mg/dL. It uses a small, 25 microliter whole blood or plasma sample which is internally diluted like the YSI, and results are available in approximately 2 minutes. Nova Primary's large color touchscreen display and intuitive, icon-based graphical user interface make it very straightforward to use. A single calibrator pack uses RFID data management to monitor the pack expiration date and remaining samples available, eliminating the need for separate reagent bottles and daily monitoring of their levels. It has excellent correlation to the YSI glucose analyzer and is traceable to NIST glucose standards. Data download is compatible with the YSI Data Manager Desktop Software. The Nova Primary measures 17 in x 11 in x 18 in (44 cm x 28 cm x 46 cm).
More on Boston Chron
About Nova Biomedical
Incorporated in 1976 and based in Waltham, MA, Nova Biomedical is a world leader in the development and manufacturing of whole blood, point-of-care and critical care analyzers, as well as instruments for cell culture monitoring in the biotechnology market. Nova uses biosensor technology in products ranging from handheld meters for glucose self- and point-of-care testing to critical care whole blood analyzers designed for stat measurement of over 22 analytes. Nova's BioProfile line has pioneered comprehensive cell culture testing, providing over 20 critical cell culture tests for a broad range of cell culture applications. Nova employs over 1,300 people worldwide and has wholly owned subsidiaries located in Brazil, Canada, Great Britain, France, Spain, Italy, Germany, Switzerland, and Japan. Certified by the International Organization for Standardization, Nova has manufacturing operations located in the U.S. and Brazil.
More on Boston Chron
http://www.novabiomedical.com
Manufacturers of blood glucose measuring devices and clinical researchers have relied on the YSI 2300 as a reference and correlation analyzer. However, as of July 2021, YSI will no longer support the analyzer, and its discontinuation has left a void. The Nova Primary analyzer fills that need. It will be available in December, 2020 for CE regulated countries and was submitted to the U.S. FDA in November 2020.
Like the YSI 2300, Nova Primary uses a single, reusable glucose electrochemical sensor based on glucose oxidase and has a measurement range of 0-1000 mg/dL. It uses a small, 25 microliter whole blood or plasma sample which is internally diluted like the YSI, and results are available in approximately 2 minutes. Nova Primary's large color touchscreen display and intuitive, icon-based graphical user interface make it very straightforward to use. A single calibrator pack uses RFID data management to monitor the pack expiration date and remaining samples available, eliminating the need for separate reagent bottles and daily monitoring of their levels. It has excellent correlation to the YSI glucose analyzer and is traceable to NIST glucose standards. Data download is compatible with the YSI Data Manager Desktop Software. The Nova Primary measures 17 in x 11 in x 18 in (44 cm x 28 cm x 46 cm).
More on Boston Chron
- Introducing BIAMI.IO Apps Framework
- Pro Golfer Kamaiu Johnson Joins Cambridge Mobile Telematics as Brand Ambassador
- Empirix Helps CEHE Confidently Migrate to Five9 Cloud-Based Contact Center Software USA - English USA - English
- Northway Biotech Opens New Biopharmaceutical Manufacturing Facility in Greater Boston Area
- Manulife Investment Management announces new managing director of institutional distribution, southeast region
About Nova Biomedical
Incorporated in 1976 and based in Waltham, MA, Nova Biomedical is a world leader in the development and manufacturing of whole blood, point-of-care and critical care analyzers, as well as instruments for cell culture monitoring in the biotechnology market. Nova uses biosensor technology in products ranging from handheld meters for glucose self- and point-of-care testing to critical care whole blood analyzers designed for stat measurement of over 22 analytes. Nova's BioProfile line has pioneered comprehensive cell culture testing, providing over 20 critical cell culture tests for a broad range of cell culture applications. Nova employs over 1,300 people worldwide and has wholly owned subsidiaries located in Brazil, Canada, Great Britain, France, Spain, Italy, Germany, Switzerland, and Japan. Certified by the International Organization for Standardization, Nova has manufacturing operations located in the U.S. and Brazil.
More on Boston Chron
- Boston: Meet some of this year's Opportunity Fund grantees
- City Streaming TV, a Streaming Television Inc Network Launches, bringing Community and Faith Leaders into local TV's, At No Cost
- Perini Management Services, Inc. Announces Two Federal Contracts Collectively Valued at $66.9 Million
- "GLORY of HISTORY" Hip-Hop Music Video Looks At Voter's Choice
- BoatDealers.ca Surges with Record Traffic in 2020
http://www.novabiomedical.com
Source: Nova Biomedical
0 Comments
Latest on Boston Chron
- Latino Leaders Network to Honor Tucson Mayor Regina Romero with the Antonio Villaraigosa Leadership Award at the 34th Tribute to Mayors
- 40 Years in Yiddishland: The Yiddish Book Center celebrates the Klezmer Conservatory Band
- Applications being accepted for Boston school committee
- The UK's Leading Digital Marketing Agency, Finsbury Media Announces Employees Will Be Allowed To Work From Home:
- Loomis Sayles Welcomes Marques Benton as Chief Diversity, Equity and Inclusion Officer
- NMEA 2000 Development and Prototyping Boards for Marine Applications
- ICTBroadast Version 4.1, Advance call center software for your needs
- Former US Deputy Assistant Secretary of Defense Dr. Joe Felter joins 6K's Advisory Board
- BrickBio Creates Novel Class of Bispecific Antibody Drug Conjugate and Receives Green Light on Next Phase of Therapeutic Deal with Large Pharma Partner
- Foundation Medicine Announces Executive Leadership Transition
- CEO of Industrial Giant ABB in Brazil Joins CEO Coaching International
- EdiGene Announces Approval of its IND Application for its CRISPR/Cas 9 Gene-editing Hematopoietic Stem Cell Therapy ET-01 in β-thalassemia by China National Medical Products Administration
- Fighting Pest Problems with The Safest Pest Control Dubai Residents Can Get
- Best Advertising Methods To Attract People To Your Events Post COVID-19 by Duluth Businessman Ismail Sirdah
- Passage of legislation to support creation of affordable housing, workforce training in Boston celebrated
- Boston: 2021 day of celebration to honor Rev. Dr. Martin Luther King Jr.
- City houses 1,700 children experiencing housing instability through Boston housing authority vouchers
- Thirteen MBK Senior Living Communities Receive "2021 Best of Senior Living" Distinction
- Grassroots Advocacy Group Urges Biden Administration to Appoint a Doctoral Level Mental Health Professional to Lead SAMHSA
- Boston: January 2021: Latest updates from the Department of Neighborhood Development